New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer

International Journal of Cancer

Volumn 88, Issue 2, 2000, Pages 260-266

  Van Hattum, Annemarie H ^a   Pinedo, Herbert M ^a   Schlüper, Hennie M M ^a   Hausheer, Frederick H ^b   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BioNumerik Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [(2 TRIMETHYLSILYL)ETHYL]CAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; IRINOTECAN; KARENITECIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; COLON CANCER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; XENOGRAFT;

ANIMAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COLONIC NEOPLASMS; COMPARATIVE STUDY; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; FEMALE; HUMAN; LUNG NEOPLASMS; MELANOMA; MICE; MICE, NUDE; NEOPLASMS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033809224     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001015)88:2<260::AID-IJC18>3.0.CO;2-Q     Document Type: Article

References (27)

1. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
2. An overview of topoisomerase I-targeting agents
3. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells
4. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P
5. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex
6. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
7. Immunochemical detection of the multi-drug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies
8. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
9. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines
10. Karenitecins (Part II): A novel class of orally active highly lipophilic topoisomerase I inhibitors
11. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SKandF 104864), a new camptothecin analogue
12. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin
13. Major vault protein LRP-related multi-drug resistance
14. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma
15. CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants
16. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein
17. DNA topoisomerase poisons as antitumor drugs
18. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
19. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies
20. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
21. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance
22. Overexpression of a M(r) 110,000 vesicular protein in non-P- glycoprotein-mediated multidrug resistance
23. Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors
24. CPT-11 converting enzyme from rat serum: Purification and some properties
25. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
26. Plant Antitumor Agents. I. The isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata
27. Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I